Data / Public companies / Connecticut / Pharmaceutical preparations
Pharmaceutical preparations companies in Connecticut: 9 that file annual reports with the SEC
9 companies that file annual reports with the SEC have a business address in Connecticut and the industry code SIC 2834 (Pharmaceutical preparations), in the SEC Financial Statement Data Sets filed through September 30, 2026. 4 report revenue, a combined $613.1 million. 11.1% of the 9 that report net income show a profit. The largest by revenue is Mannkind Corp ($349.0 million).
SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.
- SIC code
- 2834
- Companies with an annual report in the data
- 9
- Companies that report revenue
- 4
- Combined revenue
- $613.1 million
- Median revenue
- $131.7 million
- Reported a net profit
- 1 of 9 (11.1%)
- Combined total assets
- $2.43 billion
- Large accelerated filers
- 2
- Newest annual report filed
- September 28, 2026
Largest by revenue
Latest fiscal year, from each company's annual report. Each name links to the company's page.
| Company | Business address | Revenue | Net income | Total assets | Revenue change |
|---|---|---|---|---|---|
| Mannkind Corp | Danbury, CT | $349 million | $5.9 million | $792.2 million | 22.2% |
| Arvinas, Inc. | New Haven, CT | $262.6 million | $-80,800,000 | $717.9 million | -0.3% |
| Rallybio Corp | New Haven, CT | $858,000 | $-8,978,000 | $62.3 million | 34.9% |
| Bioxcel Therapeutics, Inc. | New Haven, CT | $642,000 | $-69,897,000 | $44.9 million | -71.7% |
Companies by size of revenue
Companies that report revenue, by the revenue in their latest annual report.
| Revenue | Companies | Share |
|---|---|---|
| Under $10 million | 2 | 50% |
| $100 million to $1 billion | 2 | 50% |
Cities with the most companies
By city of the business address.
| City | Companies | Share |
|---|---|---|
| New Haven | 6 | 66.7% |
| Branford | 1 | 11.1% |
| Danbury | 1 | 11.1% |
| Shelton | 1 | 11.1% |
Newest annual reports
By the date the company filed its latest annual report with the SEC.
| Company | Filed | Fiscal year ended | Form | Revenue |
|---|---|---|---|---|
| Nanoviricides, Inc. | September 28, 2026 | June 30, 2026 | 10-K | Not listed |
| Veradermics, Inc | March 30, 2026 | December 31, 2025 | 10-K | Not listed |
| Bioxcel Therapeutics, Inc. | March 27, 2026 | December 31, 2025 | 10-K | $642,000 |
| Trevi Therapeutics, Inc. | March 17, 2026 | December 31, 2025 | 10-K | Not listed |
| Rallybio Corp | March 16, 2026 | December 31, 2025 | 10-K | $858,000 |
| Biohaven LTD. | March 2, 2026 | December 31, 2025 | 10-K | Not listed |
| Azitra, Inc. | February 27, 2026 | December 31, 2025 | 10-K | $0 |
| Mannkind Corp | February 26, 2026 | December 31, 2025 | 10-K | $349 million |
| Arvinas, Inc. | February 24, 2026 | December 31, 2025 | 10-K | $262.6 million |
Filer category
The SEC's size class for the company when it filed.
| Category | Companies | Share |
|---|---|---|
| Non-accelerated filer | 6 | 66.7% |
| Large accelerated filer | 2 | 22.2% |
| Accelerated filer | 1 | 11.1% |
Updated September 30, 2026. Read from SEC Financial Statement Data Sets (sec.gov). Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.